Evidence map›Paper›PMID 32061635›Full record

ArticleProgress in cardiovascular diseases

Nutraceuticals have potential for boosting the type 1 interferon response to RNA viruses including influenza and coronavirus.

Mark F McCarty, James J DiNicolantonio

Abstract read
In one paragraph

Article in Progress in cardiovascular diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Trial
  5. Review
  6. Review
  7. Review
  8. Review
  9. The "Magnificent Seven" in Oral and Systemic Health against COVID-19.Endocrine, metabolic & immune disorders drug targets · 2025
    Review
  10. Review
  11. Review
  12. Phenolic Compounds inMolecules (Basel, Switzerland) · 2023
    Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Deciphering the immunoboosting potential of macro and micronutrients in COVID support therapy.Environmental science and pollution research international · 2022
    Review

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Mark F McCartyCatalytic Longevity Foundation, United States of America.
James J DiNicolantonioMid America Heart Institute, St. Luke's Hospital, United States of America. Electronic address: jjdinicol@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Dietary SupplementsAnimalsAntioxidantsAntiviral AgentsBetacoronavirusCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentEnzyme InhibitorsHost Microbial InteractionsHumansHydrogen PeroxideImmunologic FactorsInfluenza, HumanInterferon Type INADPH Oxidase 2AntioxidantsAntiviral AgentsCYBB protein, humanEnzyme InhibitorsHydrogen PeroxideImmunologic FactorsInterferon Type INADPH Oxidase 2TLR7 protein, humanToll-Like Receptor 7

Identifiers

PMID32061635
PMCPMC7130854

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.